মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), menthol, unspecified form (unii: l7t10eip3a) (menthol, unspecified form - unii:l7t10eip3a) - topical anesthetic topical analgesic temporarily relieves pain and itching due to:

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cystic fibrosis - other respiratory system products - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4.4 and 5.1).in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5.1).kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4.4 and 5.1).in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

মাল্যাশিয়া - ইংরেজি - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

averroes pharmaceuticals sdn. bhd. - rosuvastatin calcium -

মাল্যাশিয়া - ইংরেজি - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

malaysian pharmaceutical industries sdn. bhd. - olanzapine -

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 50mg;  ;   - oral granules - 50 mg - active: ivacaftor 50mg     excipient: colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate lactose monohydrate magnesium stearate mannitol sodium laurilsulfate sucralose - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 75mg;  ;   - oral granules - 75 mg - active: ivacaftor 75mg     excipient: colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate lactose monohydrate magnesium stearate mannitol sodium laurilsulfate sucralose - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 25mg;   - oral granules - 25 mg - active: ivacaftor 25mg   excipient: colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate lactose monohydrate magnesium stearate mannitol sodium laurilsulfate sucralose - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

peer pharm ltd. - octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), homosalate (unii: v06sv4m95s) (homosalate - unii:v06sv4m95s), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox) - octocrylene 5 g in 100 ml

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

innocutis holdings llc - bionect is indicated for the dressing and management of partial to full thickness dermal ulcers (pressure sores, venous stasis ulcers, arterial ulcers, diabetic ulcers), wounds including cuts, abrasions, donor sites, and post operatice incisions, irritations of the skin, and first and second degree burns, the dressing is intended to cover a wound or burn on a patient's skin, and protect against abrasion, friction and desiccation.

যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

vertex pharmaceuticals (uk - ivacaftor - tablet - 150mg